KR20150043342A - 단일 가변 도메인 및 카모스타트 메실레이트 (cm)를 포함하는 조성물 - Google Patents

단일 가변 도메인 및 카모스타트 메실레이트 (cm)를 포함하는 조성물 Download PDF

Info

Publication number
KR20150043342A
KR20150043342A KR20157004323A KR20157004323A KR20150043342A KR 20150043342 A KR20150043342 A KR 20150043342A KR 20157004323 A KR20157004323 A KR 20157004323A KR 20157004323 A KR20157004323 A KR 20157004323A KR 20150043342 A KR20150043342 A KR 20150043342A
Authority
KR
South Korea
Prior art keywords
leu
ser
ala
gly
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20157004323A
Other languages
English (en)
Korean (ko)
Inventor
션 매튜 클리블랜드
스테판 살로몬
카산드라 밴 크린크스
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20150043342A publication Critical patent/KR20150043342A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR20157004323A 2012-08-21 2013-08-21 단일 가변 도메인 및 카모스타트 메실레이트 (cm)를 포함하는 조성물 Withdrawn KR20150043342A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691443P 2012-08-21 2012-08-21
US61/691,443 2012-08-21
PCT/IB2013/001814 WO2014030049A2 (en) 2012-08-21 2013-08-21 Compositions comprising a single variable domain and camostat mesylate (cm)

Publications (1)

Publication Number Publication Date
KR20150043342A true KR20150043342A (ko) 2015-04-22

Family

ID=49510445

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20157004323A Withdrawn KR20150043342A (ko) 2012-08-21 2013-08-21 단일 가변 도메인 및 카모스타트 메실레이트 (cm)를 포함하는 조성물

Country Status (11)

Country Link
US (1) US20150306058A1 (enExample)
EP (1) EP2887960A2 (enExample)
JP (1) JP2015527357A (enExample)
KR (1) KR20150043342A (enExample)
CN (1) CN104884089A (enExample)
AU (1) AU2013304627A1 (enExample)
BR (1) BR112015003851A2 (enExample)
CA (1) CA2882684A1 (enExample)
IN (1) IN2015DN01147A (enExample)
RU (1) RU2015110027A (enExample)
WO (1) WO2014030049A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190003493A (ko) * 2016-03-31 2019-01-09 브이에이치스퀘어드 리미티드 조성물

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
BR112017010793A2 (pt) * 2014-11-24 2017-12-26 Regeneron Pharma animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
ES2984656T3 (es) * 2015-05-13 2024-10-30 Ablynx Nv Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
BR112018012352A2 (pt) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
US12570736B2 (en) 2019-06-21 2026-03-10 Sorriso Pharmaceuticals, Inc. Compositions
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CA3171958A1 (en) * 2020-03-18 2021-09-23 Memorial Sloan Kettering Cancer Center Inhalational therapy for covid-19

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190003493A (ko) * 2016-03-31 2019-01-09 브이에이치스퀘어드 리미티드 조성물

Also Published As

Publication number Publication date
BR112015003851A2 (pt) 2017-08-08
JP2015527357A (ja) 2015-09-17
CA2882684A1 (en) 2014-02-27
CN104884089A (zh) 2015-09-02
WO2014030049A2 (en) 2014-02-27
IN2015DN01147A (enExample) 2015-06-26
EP2887960A2 (en) 2015-07-01
RU2015110027A (ru) 2016-10-10
US20150306058A1 (en) 2015-10-29
WO2014030049A3 (en) 2014-04-17
AU2013304627A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
US20150306058A1 (en) Composition comprising a single variable domain and camostat mesylate (cm)
US11939361B2 (en) Compositions of peptide inhibitors of Interleukin-23 receptor
JP6858174B2 (ja) インターロイキン２３受容体のペプチド阻害剤、および炎症性疾患を処置するためのそれらの使用
JP7057360B2 (ja) 抗－ｃｄ３抗体製剤
ES2977537T3 (es) Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales
ES2973042T3 (es) Polipéptidos
CA3033004A1 (en) Stable peptides and methods of use thereof
JP2020505352A (ja) インターロイキン−２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
WO2017120523A2 (en) Anti-pro/latent myostatin antibodies and methods of use thereof
AU2026201037A1 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
US20200188471A1 (en) Application of selective tnfr1 antagonist peptide sn10 in preparation of drugs for preventing and treating rheumatoid arthritis
KR20170132749A (ko) 폴리펩티드
JP2010229138A5 (enExample)
CN105979957A (zh) 细菌通过模拟α-MSH的CLPB蛋白对宿主进食与情绪的影响
Li et al. N-terminal capping of the αo-conotoxin analogue gex-2 improves the serum stability and selectivity toward the human α9α10 nicotinic acetylcholine receptor
KR20150043343A (ko) 항체 및 카모스타트 메실레이트 (cm)를 포함하는 조성물
CN101068560B (zh) 毒素中和性肽的筛选方法和STX2抑制性肽以及Vero毒素中和剂
US20170342136A1 (en) Monoclonal antibody against muramyl peptides in prevention and treatment of immune-mediated diseases
HK40092077A (en) Compositions of peptide inhibitors of interleukin-23 receptor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid